Klin Monbl Augenheilkd 2021; 238(04): 454-457
DOI: 10.1055/a-1384-1056
Der interessante Fall

Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema

Persistente Reste des intravitrealen Dexamethason-Implantats nach 24 Monaten bei einem Patienten mit Vorder- und Mittelstufe einer Uveitis, im Zusammenhang mit einem Makulaödem
1   Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland
,
Jean Vaudaux
1   Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland
2   Ophthalmology, Private practice, Morges, Switzerland
,
Jean-Antoine Pournaras
1   Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland
,
Aude Ambresin
1   Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland
3   Opthalmology Departement, Swiss Visio, Clinique de Montchoisi, Lausanne, Switzerland, Lausanne, Switzerland
› Institutsangaben

Introduction

Several retinal diseases, including diabetic retinopathy, retinal vein occlusion, uveitis, wet age-related macular degeneration, complicated or uncomplicated ophthalmic surgery, and invasive treatment such as radiotherapy for ocular malignancy could be responsible for macular edema (ME), which is nowadays considered a leading cause of vision loss. It has been proven that chronic ME is associated with visual deterioration [1], [2], [3], [4]. In order to prevent irreversible visual deterioration and other complications, ME is an indication for treatment with corticosteroids, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) [5].



Publikationsverlauf

Eingereicht: 24. September 2020

Angenommen: 29. Januar 2021

Artikel online veröffentlicht:
30. April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany